Abstract: Systems for and methods of readily locating an eyewash station in a lab while visually impaired are provided.

Abstract: A sexual interaction device for use as an input device for a virtual reality erotic application comprising a body part engaging portion (6, 9, 11, 13, 15) and a distance measurement unit (5). In order to allow for a reliable synchronisation between the user's motion and a virtual environment, it is provided according to the invention that the distance measurement unit (5) comprises an ultrasonic sensor (1) assembly operatively coupled to the body part engaging portion (6, 9, 11, 13, 15).

Abstract: A medical procedure for improving human sexual function in a patient is disclosed. The medical procedure includes drawing blood from the patient, processing the blood that was drawn to produce platelet rich plasma (PRP) from said blood, and anesthetizing a portion of a penile shaft of a male patient or anesthetizing a portion of a vulva and an anterior vaginal wall of a female patient. The medical procedure also includes applying extra corporeal shockwave therapy to portions of the penis (in a male patient) or portions of the vulva (in a female patient) using an extra corporeal shockwave generator system, and injecting the platelet rich plasma produced from said blood into at least one location on the perineal area of the patient.

Abstract: A liquid circulation member for a massage device includes a body and a seal. The body has a room defined therein, and a path is formed at the inner bottom of the room. The seal is shaped to be matched with the body. The seal has a layer of glue spread on outside thereof so as to be connected to the body to seal the path. The seal has an inlet and an outlet to allow liquid to circulate via the path. Multiple vibration motors are connected to outside of the seal and located in the room of the body to massage the user's muscles.

Abstract: A cardiopulmonary resuscitation coordination method is disclosed.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: The present invention provides a lid cover (1) of a medicine container (2) for preventing a medicine, which is air-tightly stored in a medicine container (2) that has a lid portion (22) that can be pierced with a needle (33), from leaking to an outside space when the medicine is suctioned using a syringe (3) having the needle (33), the lid cover (1) including a peripheral wall portion (10) that can be mounted to the lid portion (22) so as to surround a piercing face of the lid portion (22) that is pierced with the needle (33) and a ceiling face portion (50) that is continuous with an upper portion of the peripheral wall portion (10), and can be pierced with the needle (33), wherein the peripheral wall portion (10) and the ceiling face portion (50) are made of an elastic material, and are configured to air-tightly store the piercing face such that the piercing face is not exposed to the outside space in a state where the peripheral wall portion (10) is mounted to the lid portion (22), while also forming a clos

Abstract: In order significantly to reduce the risk of contamination of a bag for medical purposes, in particular due to residual particles of tube material caused during cutting of a tube for access to the bag, the invention proposes a system (1) for producing a bag for medical purposes, comprising a tube transfer station (2) with a transfer means (3) for transferring a tube (11) coming into the tube transfer station (2) to a holder (10) and for the severing there of a tube section (17) transferred to the holder (10) from a remaining portion (18) of the incoming tube (11) in order subsequently to be able to make the severed tube section (17) connectable to two film layers for forming an access to the bag, wherein the tube transfer station (2) has a tube-tension-holding means (15) on the holder side and also a tube-pulling means (16), which means are designed to introduce tensile forces (19) between the severed tube section (17) and the remaining portion (18) of the incoming tube (11) while the severing takes place.

Abstract: The present invention relates to a medical device connector for connecting a piercing device, with a vial comprising a base member. A plurality of grip members, each grip member comprising a distal end (D) and a proximal end (P) and each comprising a wedge portion adapted to temporarily or permanently lock the medical device connector to the vial. The base member further comprises a plurality of flanges, wherein the proximal ends (P) of the grip members are arranged to the flanges. The flanges extend substantially out from the periphery of the base member in a direction substantially perpendicular to the direction of the grip members, wherein the space formed between the flanges of the base member forms at least one grip portion. The present invention provides for a medical device connector which is easy and comfortable to use, which provide good stacking capabilities and which permits a user to readily acknowledge that the medical device connector is correctly assembled with the vial.

Abstract: An automatic or semi-automatic preparation system and process is provided for forming a medicament solution from a vial containing one of a liquid and a non-liquid material.

Abstract: A robotic capsule filling machine system is disclosed. In particular, the system may include a robotic capsule filling machine that is controlled by a computing device, such as a tablet. An application executing on the computing device may be utilized by a user to create a capsule formulation to be dispensed in capsules to be filled by the robotic capsule filling machine. Various inputs into the application may include, but are not limited to, a capsule size, a purity, a density, and a batch size. Based on the inputs, the system may translate the inputs to determine the desired capsule formulation. If the capsule formulation is valid, the system may cause the robotic capsule filling machine to extract an amount of the capsule formulation from one or more reservoirs. The robotic capsule filling machine may then proceed to dispense the extracted amount of capsule formulation into a plurality of capsules.

Abstract: There is provided a modular medication dispensing system for managing and automatically dispensing pills from a plurality of portable medication dispensers, the modular system comprising: a base equipped with rotation means and being removably installed on a plane surface, a circular magazine comprising a plurality of adaptors for receiving a plurality of portable medication dispensers, the circular magazine being rotatably mounted on the base, an actuator for actuating a portable dispenser from the plurality of portable dispensers when the portable dispenser is in the dispensing position, a plurality of autonomous portable dispensers being removably received in the plurality of adaptors and operating autonomously or in synchronization with the modular system, a filling assembly comprising movable means for automatically filling a portable dispenser, and an electronic system comprised in each portable dispenser and in the base for permanently communicating between the plurality of portable dispensers and the

Abstract: Devices, systems, and software for providing remote medical therapy to a subject comprising: an apparatus for dispensing one or more medical items from an inventory of medical items, the inventory of medical items risk profiled to a subject, a population, a venue, or a situation; and a connector device comprising: at least one means for communicating with the apparatus for dispensing one or more medical items from an inventory of medical items; at least one means for communicating with a technology device; and a software module enabling communications between the apparatus for dispensing one or more medical items from an inventory of medical items and the technology device.

Abstract: A container gripping aid (1) has a jacket (2) for reception of a container such as a baby bottle (3). The jacket (2) has a mesh configuration with a plurality of through-holes (5) to facilitate gripping of the jacket (2) by a baby. The jacket (2) has an egg-like shape. Thus, when it is engaged with the bottle (3), most of the jacket (2) side wall is supported spaced-apart from an exterior side wall (6) of the container (3) which enables a baby to easily grip the mesh of the jacket (2).

Abstract: Methods and apparatus for an enteral feeding pump system. A method of directing flow for a coil includes drawing fluid from a source and delivering fluid, the coil including input and output check valves to prevent a back flow of fluid.

Abstract: Certain embodiments are directed to methods, apparatuses, and systems for providing accurate, non-intrusive measurement of breastfeeding. The embodiments described herein are used during the normal breastfeeding routine and measure the volume of breast milk transferred in real time. The device is lightweight, disposable, and does not interfere with the milking mechanisms used by infants. The device provides a more accurate monitoring of infant nutrition and peace of mind for mothers.

Abstract: The present disclosure provides low water dentifrice compositions comprising an effective amount of a zinc ion source, a stannous ion source, a polyphosphate and an acid in a calcium pyrophosphate base. The acid lowers the pH of the composition to enable stabilization of the metal ions and extend shelf-life of the composition.

Abstract: The present invention aims to provide a high quality cosmetic which can maintain a certain color before use regardless of storage conditions or lot. The present invention relates to an oily cosmetic that can control the coloring after its application by comprising a certain amount of a specific C16-18 fatty acid, a process for producing the same, and a method for controlling the coloring thereof.

Abstract: The present invention relates to a cosmetic composition comprising between 20 and 45% of a first surfactant, from 0.1 and 22% of a second surfactant; and cosmetically acceptable adjuvants for use in hair cleaning and color maintenance of dyed hair, which can be used as a shampoo and other hair formulations.

Abstract: The present disclosure relates to cosmetic agents for the reductive decoloration of colored keratinous fibers, more particularly human hair, containing a sulphinic acid derivative and at least one alcohol with from about 10 to about 30 carbon atoms. This combination is able to reduce the unpleasant odor during the decoloration process. The present disclosure also relates to a corresponding kit-of-parts, the use of cosmetic agents and the kit-of-parts, as well as to an application method using the cosmetic agents and the packaging unit.

Abstract: The present disclosure relates to a cosmetic cleansing composition which contains at least one nonionic surfactant having the following formula (I) R1CO—N(R2)—CH2—CH(OH)—CH(OH)—CH(OH)—CH(OH)—CH2OH??(I), wherein R1CO denotes a straight-chained or branched, saturated or unsaturated C8-C22-acyl radical and R2 denotes a C1-C4-alkyl radical and at least one polyethylene glycol of a molar mass MW with an average mass of 1,000,000 to 10,000,000 Dalton is contained. The cosmetic cleansing compositions are storage- and temperature-stable and generate large amounts of a dense, creamy foam which can be distributed well and glides on the skin and can also be rinsed off well and leaves a smooth, soft and nourished skin feeling. The cleansing agents also have a very pleasant texture. With an additional content of special thickening agents, the rheology and removability of the cleansing agents from the respective container can be controlled and/or adjusted particularly well.

Abstract: The invention relates to a topically applied cosmetic reductive composition containing up to 20 wt. % of hydrolysed keratin and sulphur. The remaining components are: water, compatibilisers, surfactants, thickeners, preservatives and/or aromatics. Said cosmetic composition can be used to reduce adipose tissue in different areas of the body.

Abstract: It is an object to provide an oral composition, a food, or a beverage and a remineralizing agent having excellent action of remineralizing demineralized tooth enamel. The present invention is an oral composition, a food, or a beverage comprising sodium chondroitin sulfate and a calcium phosphate. The present invention is a tooth remineralizing agent comprising sodium chondroitin sulfate and a calcium phosphate as active ingredients.

Abstract: Cosmetic agents and methods for temporarily shaping keratin-containing fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent includes a cosmetic carrier. The cosmetic agent further includes at least one chitosan or derivative thereof. The cosmetic agent further includes at least one hydrophobic pyrogenic silicic acid. The cosmetic agent also includes at least one non-ionic, anionic, or amphoteric film-forming polymer. In another embodiment, the method includes the step of using the cosmetic agent for temporarily shaping keratin-containing fibers.

Abstract: A cosmetic composition comprising a cosmetically active ingredient in a cosmetically acceptable medium, wherein the cosmetic composition contains a silicone composition comprising (A) a hydrophobic organopolysiloxane fluid having a surface tension of from 15 to 40 mN/m and (B) a finely divided solid hydrophobic filler dispersed in the organopolysiloxane fluid (A).

Abstract: The present invention relates to an anti-cell senescence cosmetic composition that comprises one or more derivatives of Casearia sylvestries, Hymenaea courbaril, or mixtures thereof, and cosmetically acceptable excipients, as well as uses thereof and related prevention methods.

Abstract: Suggested is a cosmetic composition comprising an anti-pollution agent selected from the group consisting of ginger root C02 extract, E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one, sclareolide, purple coneflower pressed juice or mixtures thereof, in a working amount sufficient for (a) reducing or preventing air pollution induced gene expression, and/or (b) reducing or preventing a gene expression induced or inducible by polycyclic aromatic hydrocarbons, and/or (c) reducing or preventing air pollution-induced or air pollution-inducible skin damage.

Abstract: The present invention relates to gentiopicroside free Gentiana acaulis and/or Gentiana septemfida extracts. Furthermore, it relates to cosmetic compositions comprising such gentiopicroside free Gentiana acaulis or Gentiana septemfida extract, as well as mixtures thereof.

Abstract: The invention relates to the fields of microbiology and health care, in particular to means and methods for minimizing the spread of hospital-acquired (HA) infections e.g. between patients and healthcare workers. Provided is an antimicrobial composition comprising an antimicrobial agent, a pharmaceutically acceptable carrier material and a polymer, the polymer being an N-vinyl lactam copolymer, and the composition being capable of forming a slow release antimicrobial film when applied to a skin surface.

Abstract: Disclosed is a liquid preparation for external application, which has a shortened transdermal absorption lag time and has excellent transdermal absorption properties. Also, disclosed is a liquid preparation for external application, which is less irritative to skin. The problems can be solved by a transdermal liquid preparation containing: (a) propylene glycol in an amount of 40 to 98% by weight; (b) phosphatidylcholine in an amount of 0.1 to 5% by weight; (c) oleyl alcohol and/or isostearyl alcohol in an amount of 0.1 to 10% by weight; and (d) a medicine in an amount of 0.1 to 25% by weight. It is preferred that the transdermal liquid preparation additionally contains an alkanol amine. The alkanol amine is preferably triethanolamine.

Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.

Abstract: The present invention teaches novel pharmaceutical compositions, dosing and treatment regimens for ENT infections, such as rhinosinusitis. The compositions can also be used by those without active rhinosinusitis to reduce and remove harmful germ dwelling and colonizing inside the nasal cavity and its surrounding passages, and prevent rhinosinusitis and other infections from happening. In one of the embodiment of the invention, the composition comprises of hydrogen peroxide, zinc chloride and sodium benzoate.

Abstract: A chewing gum composition comprising cannabinoids or derivatives thereof and gabapentin is provided. The chewing gum composition is formulated to provide controlled release of cannabinoids and gabapentin during mastication. Methods to provide post-herpetic neuralgia and restless leg syndrome treatment using the chewing gum composition according to this invention are also provided.

Abstract: Described herein are methods to purify alkaloids and amino acids. Also described are compositions and methods to treat or prevent a disease using the purified amino acids and alkaloids. The composition can be, for example, formulated into a beverage, a supplement, or formulated for use in e-cigarettes. Also described are methods of treating a disease such as Parkinson's Disease, Alzheimer's Disease, ADHD, ADD, vascular disorders, cancer, heart disorders, migraine headaches, cluster headaches, plaque reduction or aging using one or more of the purified alkaloids or amino acids.

Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

Abstract: The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Abstract: The present invention relates to a functional feed and an oral delivery system for delivery of bioactive macromolecules. The oral delivery system comprises ethylenediammonium alginate which is a vehicle for delivery of macromolecular drugs. The oral delivery system according to the present invention is particularly suitable for use in combination with functional feeds in fish.

Abstract: The invention relates to the formulation of solid pharmaceutical compounds. Further, solid pharmaceutical composition comprising a therapeutically effective amount of teriflunomide or a pharmaceutically acceptable basic addition salt thereof and excipients.

Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.

Abstract: Provided is a sustained release tablet having two-phase release-controlling system, which consists of a first release-controlling phase including pregabalin or its salt and hydroxypropyl methylcellulose; and a second release-controlling phase including polyethylene oxide as a swelling polymer, the first release-controlling phase being homogeneously dispersed in the second release-controlling phase.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions.

Abstract: The present invention is directed to a process for making a dosage form comprising at least one pharmaceutically active ingredient, the method comprising the steps of (i) providing a shape of the dosage form comprising at least two powder layers, wherein the first powder layer comprises a surface stabilizing agent and the second powder layer comprises at least one activator and the pharmaceutically active ingredient, wherein the activator has a Q value of less than 75; (ii) applying a radiofrequency energy for a sufficient period of time to the shape of step (i); and (iii) applying heat for a sufficient period of time to the shape of step (i).

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: A transdermal device is provided. The transdermal device includes a transdermal patch, a sheet-shaped electrode stacked overlying one surface of the transdermal patch, and a power source connected to the sheet-shaped electrode. The transdermal patch includes a carrier layer. The carrier layer comprises a hollow structure and an external composition. The hollow structure comprises a plurality of cells partitioned by an insulator and has hollow portions penetrating through one plane surface to the other plane surface of the hollow structure. The external composition comprises a dispersion liquid comprising a nanoparticle containing an active ingredient.

Abstract: This invention provides a compositions for transport of a therapeutic agent. The compositions contain a therapeutic agent and a monoterpene or an analog thereof. In one aspect, the monoterpene is perillyl alcohol (POH) or an analog thereof. In one aspect, the therapeutic agent is provided in an amount effective to treat the disease or subject of choice.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: The invention relates to a food additive which includes at least one clay interspersed with volatile antimicrobial agents. Such an additive can be added to the feed of certain animals, in particular poultry and ruminants, in order to act as a growth promoter and to reduce the risks of infection, as well as the risks of intoxication by mycotoxins.